Attend Pittcon 2025 in Boston to connect with global leaders in laboratory science and explore cutting-edge advancements in ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

BigHat Biosciences is adding Synaffix’s antibody-drug conjugate (ADC) tech to its wardrobe, pairing the science with its antibody design platform to tailor a next-gen ADC pipeline. | BigHat ...

data-text="Merck Announces Emerging Biotech Grant Program Winners" data-link=" Announces Emerging Biotech Grant Program ...

Theriva stock is trading higher after the company announced it was selected as a finalist for Merck's KGaA's EMEA Advance ...

Founded on the principles of innovation and patient need, Theriva™ Biologics is a diversified clinical-stage company focused on developing groundbreaking therapeutics to combat cancer and related ...

Theriva Biologics (TOVX) announced selection as one of five finalists for Merck KGaA’s EMEA Advance Biotech Grant. Finalists for the ...

Winner to be Presented at BIO-Europe 2024 in Stockholm, SwedenROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing ...

Winner to be Presented at BIO-Europe 2024 in Stockholm, SwedenROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ ...

VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI) a data-first generative AI ...

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany (Merck KGaA), invested $76 million to expand its antibody drug conjugate (ADC) manufacturing capabilities ...